[go: up one dir, main page]

SG11202113226QA - Antiarrhythmic formulation - Google Patents

Antiarrhythmic formulation

Info

Publication number
SG11202113226QA
SG11202113226QA SG11202113226QA SG11202113226QA SG11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA SG 11202113226Q A SG11202113226Q A SG 11202113226QA
Authority
SG
Singapore
Prior art keywords
antiarrhythmic
formulation
antiarrhythmic formulation
Prior art date
Application number
SG11202113226QA
Inventor
Michael Laird Hurrey
Luiz Belardinelli
Prashanti Madhavapeddi
Carlos Schuler
Original Assignee
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/901,941 external-priority patent/US11020384B2/en
Application filed by Incarda Therapeutics Inc filed Critical Incarda Therapeutics Inc
Publication of SG11202113226QA publication Critical patent/SG11202113226QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202113226QA 2019-08-01 2020-07-30 Antiarrhythmic formulation SG11202113226QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962881689P 2019-08-01 2019-08-01
US16/901,941 US11020384B2 (en) 2019-08-01 2020-06-15 Antiarrhythmic formulation
US16/901,909 US11007185B2 (en) 2019-08-01 2020-06-15 Antiarrhythmic formulation
PCT/US2020/044291 WO2021022058A2 (en) 2019-08-01 2020-07-30 Antiarrhythmic formulation

Publications (1)

Publication Number Publication Date
SG11202113226QA true SG11202113226QA (en) 2021-12-30

Family

ID=74229279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113226QA SG11202113226QA (en) 2019-08-01 2020-07-30 Antiarrhythmic formulation

Country Status (9)

Country Link
EP (1) EP4007576A4 (en)
JP (3) JP7190077B2 (en)
KR (1) KR102491733B1 (en)
CN (1) CN114144177A (en)
AU (3) AU2020323594B2 (en)
CA (1) CA3139748A1 (en)
IL (3) IL290088B2 (en)
SG (1) SG11202113226QA (en)
WO (1) WO2021022058A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2022133317A1 (en) 2020-12-17 2022-06-23 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ276305A (en) * 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
EP1809240A4 (en) * 2004-10-12 2010-06-16 Alexza Pharmaceuticals Inc Cardiac safe, rapid medication delivery
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
CN101472589A (en) * 2006-04-06 2009-07-01 先灵公司 Use of a composition comprising a thrombin receptor antagonist for the preparation of a medicament for the treatment of cardiovascular diseases
EP2413902B1 (en) * 2009-03-18 2019-07-17 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2017136421A1 (en) * 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
JP2020519628A (en) * 2017-05-10 2020-07-02 インカーダ セラピューティクス, インコーポレイテッド Unit doses, aerosols, kits and methods for treating cardiac conditions by pulmonary administration
EP3621591A1 (en) * 2017-05-11 2020-03-18 Steadymed Ltd. Enhanced solubility drug-containing formulations
GB2564444B (en) * 2017-07-10 2020-09-16 Syri Ltd Liquid pharmaceutical composition of flecainide

Also Published As

Publication number Publication date
IL290088B2 (en) 2023-10-01
IL303094A (en) 2023-07-01
IL303094B1 (en) 2025-07-01
JP7611211B2 (en) 2025-01-09
AU2020323594B2 (en) 2022-02-03
CA3139748A1 (en) 2021-02-04
IL321589A (en) 2025-08-01
IL290088B1 (en) 2023-06-01
JP2025004215A (en) 2025-01-14
WO2021022058A3 (en) 2021-04-08
JP2022533477A (en) 2022-07-22
KR102491733B1 (en) 2023-01-27
KR20230014882A (en) 2023-01-30
AU2020323594A1 (en) 2021-12-23
JP2023022251A (en) 2023-02-14
JP7190077B2 (en) 2022-12-14
AU2022202842A1 (en) 2022-05-19
IL303094B2 (en) 2025-11-01
EP4007576A2 (en) 2022-06-08
IL290088A (en) 2022-03-01
AU2022202842B2 (en) 2024-02-22
CN114144177A (en) 2022-03-04
EP4007576A4 (en) 2023-05-10
AU2024201359A1 (en) 2024-03-21
KR20220025071A (en) 2022-03-03
WO2021022058A2 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
IL282617A (en) Aerosolisable formulation
IL290447A (en) Pharmaeutical composition comprising ensifentrine
IL276011A (en) Group b adenovirus-containing formulation
IL282567A (en) Aerosolisable formulation
IL282523A (en) Aerosolisable formulation
IL282589A (en) Aerosolisable formulation
GB201816447D0 (en) Formulation
IL282461A (en) Aerosolisable formulation
IL282697A (en) Aerosolisable formulation
GB201817863D0 (en) Aerosolisable formulation
IL290088A (en) Antiarrhythmic formulation
IL284688A (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
HK40067172A (en) Antiarrhythmic formulation
HK40075133A (en) Antiarrhythmic formulation
GB2587402B (en) Formulation
GB2599912B (en) New formulation
GB202115303D0 (en) New formulation
GB202108181D0 (en) New formulation
GB201906242D0 (en) Aerosolisable formulation
GB201900658D0 (en) Formulation
GB202003048D0 (en) Formulation